Drug introduction of Ixabepilone

Ixabepilone is a semi-synthetic epithelial cytostatin derivative and is the first epothilone anti-cancer drug approved by the U.S. Food and Drug Administration (FDA). This drug is a microtubule-stabilizing agent. Its main mechanism of action is to bind to β-tubulin, promote the assembly of microtubules and inhibit its depolymerization, thereby preventing the normal division of cancer cells and inducing apoptosis. Unlike taxanes, ixabepilone is structurally stable and has less impact on multidrug resistance mechanisms, which makes it active in multiple drug-resistant tumor models.

Ixabepilone is administered intravenously, usually as an infusion every three weeks over approximately three hours. Its metabolism is mainly completed by the CYP3A4 enzyme system in the liver, so when using it, you should avoid combining it with strong CYP3A4 inhibitors or inducers. Common adverse reactions include fatigue, neuropathy, nausea, muscle pain and bone marrow suppression, but most patients can be controlled through dose adjustment and auxiliary medication.

Pharmacologically, the outstanding feature of ixabepilone is its ability to bypass the defense mechanisms of drug-resistant tumor cells. It has a lower affinity for P-glycoprotein than paclitaxel or docetaxel, thereby avoiding reduced efficacy due to drug efflux. This property makes ixabepilone show significant advantages in the treatment of taxane-resistant breast cancer.

Ixabepilone is currently mainly suitable for patients with metastatic breast cancer, especially those who have failed anthracycline and taxane treatment. Due to its unique mechanism of action and stable pharmacokinetic characteristics, this drug is regarded as one of the important options for "post-line treatment" of breast cancer globally. It is worth noting that when choosing this drug, doctors usually conduct individualized assessments based on the patient's systemic status, liver and kidney function, and previous medication history to maximize efficacy and reduce toxic reactions.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html